ALNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alnylam Pharmaceuticals Inc (ALNY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive long-term potential due to its strong product pipeline and recent partnership with Tenaya Therapeutics, the current technical indicators, financial performance, and lack of strong trading signals suggest waiting for a better entry point.
The stock is showing bearish momentum with moving averages in a downward trend (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 39.647, and the MACD is above zero but positively contracting. The stock is trading near its key support level of 318.021, indicating potential downside risk.
The partnership with Tenaya Therapeutics to validate up to 15 gene targets for heart disease, with potential milestone payments of $1.13 billion, is a significant long-term positive catalyst. Analysts remain optimistic about the company's TTR franchise and its long-term growth potential.
The stock has faced recent price target downgrades from multiple analysts, reflecting concerns over near-term headwinds and a slight miss in Q4 results. Financial performance shows a significant decline in net income and EPS, raising concerns about profitability.
In Q4 2025, revenue increased by 84.95% YoY to $1.097 billion, but net income dropped by -322.56% YoY to $186.42 million. EPS also fell by -310.77% YoY to 1.37, and gross margin decreased by 8.55% YoY to 75.6%. While revenue growth is strong, profitability metrics are deteriorating.
Analysts maintain a generally positive long-term outlook with multiple Buy ratings. However, recent price target reductions (e.g., Morgan Stanley to $360, Bernstein to $451) reflect near-term caution. The consensus highlights the strong potential of the TTR franchise but acknowledges current challenges.
